| Literature DB >> 30700255 |
E Langeland1,2, H Tuntland3,4, B Folkestad3,5, O Førland3,6, F F Jacobsen3,6, I Kjeken7,8.
Abstract
BACKGROUND: Reablement is an emerging approach in rehabilitation services, but evidence for its efficacy is rather weak and inconsistent. The purpose of the present study is therefore to investigate the health effects of reablement in home-dwelling adults.Entities:
Keywords: Activities of daily living; Adults; Clinical controlled trial; Home-care services; Reablement; Rehabilitation
Mesh:
Year: 2019 PMID: 30700255 PMCID: PMC6354362 DOI: 10.1186/s12877-019-1038-x
Source DB: PubMed Journal: BMC Geriatr ISSN: 1471-2318 Impact factor: 3.921
Fig. 1Flow chart of the trial profile
Baseline characteristics of participants allocated to reablement group or control group
| All participants ( | Reablement group ( | Control group ( |
| |
|---|---|---|---|---|
| Age, years, mean (SD) | 78.4 (10.9) | 78.2(11.2) | 79.5(9.3) | 0.22 |
| Female, | 575 (69.3) | 488 (68.7) | 87 (72.5) | 0.41 |
| Higher education, | 167 (20.3) | 140 (19.9) | 27 (22.5) | 0.52 |
| Living alone | 596 (71.6) | 502 (70.7) | 94 (78.3) | 0.38 |
| Motivation, scale 1–10, (10 is highest), mean (SD) | 8.1 (2.1) | 8.2 (2.0) | 7.4 (2.6) | < 0.001 |
| COPMb-Pc, scale 1–10, (10 is highest), mean (SD) | 3.54 (1.62) | 3.46 (1.61) | 4.00 (1.91) | 0.01 |
| COPMb-Sd, scale 1–10, (10 is highest), mean (SD) | 3.41 (1.82) | 3.31 (1.81) | 4.14 (2.1) | < 0.001 |
aDifference between groups (independent-sample t tests for means and χ2 tests for proportions). SD standard deviation of the mean
bCanadian Occupational Performance Measure, cActivity performance, d Satisfaction with performance
Major health challenge
| The whole sample ( | Intervention-group ( | Control-group ( | ||||
|---|---|---|---|---|---|---|
| Major health challenge |
| % |
| % |
| % |
| Fracture | 168 | 20.3 | 149 | 20.9 | 19 | 15.7 |
| Dizziness/balance problems | 125 | 15.1 | 113 | 15.9 | 12 | 9.9 |
| Pain | 82 | 9.9 | 70 | 9.8 | 12 | 9.9 |
| Stroke | 75 | 9.1 | 66 | 9.3 | 9 | 7.4 |
| Arthritis | 62 | 7.5 | 47 | 6.6 | 15 | 12.4 |
| Heart disease | 49 | 5.9 | 37 | 5.2 | 12 | 9.9 |
| Orthopedic disease | 37 | 4.5 | 29 | 4.1 | 8 | 6.6 |
| Neurological disease other than stroke | 32 | 3.9 | 25 | 3.5 | 7 | 5.8 |
| Pulmonary disease | 31 | 3.7 | 29 | 4.1 | 2 | 1.7 |
| Back disease/problem | 20 | 2.4 | 17 | 2.4 | 3 | 2.5 |
| Movement challenges/functional decline | 20 | 2.4 | 16 | 2.3 | 4 | 3.3 |
| Sight problems/eye disease | 19 | 2.3 | 13 | 1.8 | 6 | 5.0 |
| Cancer | 19 | 2.3 | 16 | 2.3 | 3 | 2.5 |
| Mental health problems | 13 | 1.6 | 13 | 1.8 | – | – |
| Amputation(s) | 12 | 1.5 | 11 | 1.5 | 1 | 0.8 |
| Diabetes | 11 | 1.3 | 10 | 1.4 | 1 | 0.8 |
| Digestion disease | 7 | 0.8 | 7 | 1.0 | – | – |
| Urinary infection | 7 | 0.8 | 5 | 0.7 | 2 | 1.7 |
| Sleep disease/problems | 3 | 0.4 | 3 | 0.4 | – | – |
| Other health challengesa | 36 | 4.5 | 33 | 4.6 | 3 | 3.3 |
| Number of additional health conditions mean (SD), min-max | 2 (2.06), 0–11 | 2 (2.04), 0–11 | 2 (2.17), 0–9 | |||
aHealth challenges that did not fit into the predefined categories
Mean (95% confidence interval (CI)) for treatment effects, estimated by a mixed-model linear repeated measures analysisa
| Reablement group Mean (95% CI) |
| Control group Mean (95% CI) |
| Treatment effect Mean (95% CI) |
| |
|---|---|---|---|---|---|---|
|
| ||||||
| Activity performance COPMb-P (1–10, 10 is high) | ||||||
| Baseline | 3.46 (3.24, 3.68) | 707 | 4.00 (3.61, 4.40) | 120 | 0.01 | |
| 10 weeks | 3.19 (2.98, 3.40) | 588 | 1.57 (1.12, 2.02) | 107 | 1.61 (1.13, 2.10) | < 0.001 |
| 6 months | 3.19 (2.91, 3.46) | 546 | 1.77 (1.21, 2.33) | 97 | 1.42 (0.82, 2.02) | < 0.001 |
| 12 months | 2.76 (2.38, 3.15) | 294 | 1.95 (1.17, 2.74) | 52 | 0.81 (−0.04, 1.66) | 0.06 |
| Satisfaction with performance COPMb-S (1–10, 10 is high) | ||||||
| Baseline | 3.31 (3.07, 3.54) | 705 | 4.14 (3.71, 4.57) | 120 | < 0.001 | |
| 10 weeks | 3.43 (3.23, 3.64) | 585 | 1.96 (1.50, 2.42) | 107 | 1.47 (0.98, 1.97) | < 0.001 |
| 6 months | 3.41 (3.15, 3.67) | 543 | 2.04 (1.48, 2.61) | 95 | 1.37 (0.77, 1.98) | < 0.001 |
| 12 months | 3.14 (2.74, 3.54) | 294 | 2.51 (1.70, 3.32) | 52 | 0.63 (− 0.26, 1.51) | 0.16 |
|
| ||||||
| SPPBc Total score (0–12, 12 is high) | ||||||
| Baseline | 4.83 (4.50, 5.15) | 697 | 5.61 (4.99, 6.23) | 121 | 0.02 | |
| 10 weeks | 1.72 (1.48, 1.96) | 574 | 0.39 (− 0.10, 0.88) | 109 | 1.33 (0.80, 1.86) | < 0.001 |
| 6 months | 1.65 (1.39, 1.91) | 530 | 0.42 (− 0.13, 0.96) | 96 | 1.23 (0.65, 1.82) | < 0.001 |
| 12 months | 1.46 (1.08, 1.84) | 278 | 0.42 (− 0.34, 1.17) | 52 | 1.03 (0.19, 1.86) | 0.02 |
| SPPB Balance (0–4, 4 is best) | ||||||
| Baseline | 2.25 (2.11, 2.38) | 697 | 2.39 (2.11, 2.67) | 121 | 0.34 | |
| 10 weeks | 0.47 (0.35, 0.59) | 573 | 0.13 (−0.11,0.37) | 109 | 0.34 (0.09, 0.59) | 0.01 |
| 6 months | 0.42 (0.31, 0.53) | 529 | 0.05 (− 0.18, 0.29) | 96 | 0.36 (0.11, 0.62) | 0.01 |
| 12 months | 0.27 (0.13, 0.41) | 278 | 0.10 (−0.21, 0.40) | 52 | 0.17 (−0.16, 0.51) | 0.31 |
| SPPB Walking (0–4, 4 is best) | ||||||
| Baseline | 1.80 (1.67, 1.94) | 697 | 2.12 (1.87, 2.37) | 121 | 0.02 | |
| 10 weeks | 0.56 (0.45, 0.67) | 570 | 0.19 (−0.02, 0.40) | 109 | 0.37 (0.15, 0.59) | < 0.001 |
| 6 Months | 0.54 (0.40, 0.67) | 529 | 0.17 (−0.08,0.43) | 96 | 0.36 (0.09, 0.63) | 0.01 |
| 12 Months | 0.46 (0.32, 0.61) | 278 | 0.31 (0.01, 0.62) | 51 | 0.15 (−0.18, 0.48) | 0.38 |
| SPPB Sit-to-stand (0–4, 4 is best) | ||||||
| Baseline | 0.79 (0.69, 0.89) | 696 | 1.05 (0.84, 1.27) | 121 | 0.03 | |
| 10 weeks | 0.72 (0.63, 0.81) | 569 | 0.11 (−0.09, 0.31) | 109 | 0.61 (0.39, 0.83) | < 0.001 |
| 6 Months | 0.71 (0.61, 0.80) | 528 | 0.25 (0.02, 0.47) | 96 | 0.46 (0.21, 0.70) | < 0.001 |
| 12 Months | 0.69 (0.53, 0.85) | 278 | 0.20 (−0.15, 0.55) | 51 | 0.49 (0.11, 0.87) | 0.01 |
| EQ-5D-5 L Mobility (1–5, 1 is best) | ||||||
| Baseline | 2.84 (2.75, 2.94) | 696 | 2.65 (2.45, 2.85) | 121 | 0.08 | |
| 10 weeks | −0.61 (− 0.68, − 0.54) | 579 | − 0.12 (− 0.29, 0.05) | 103 | −0.49 (− 0.68, − 0.31) | < 0.001 |
| 6 months | −0.57 (− 0.64, − 0.49) | 542 | −0.20 (− 0.38, − 0.01) | 97 | −0.37 (− 0.57, − 0.17) | < 0.001 |
| 12 months | −0.48 (− 0.59, − 0.36) | 288 | −0.27 (− 0.54, − 0.01) | 54 | 0.20 (− 0.49, 0.08) | 0.17 |
| EQ-5D-5 L Personal care (1–5, 1 is best) | ||||||
| Baseline | 2.04 (1.93, 2.15) | 697 | 1.83 (1.62, 2.04) | 121 | 0.07 | |
| 10 weeks | −0.48 (− 0.54, − 0.42) | 581 | − 0.12 (− 0.26, 0.02) | 103 | −0.36 (−-0.51, − 0.21) | < 0.001 |
| 6 months | −0.40 (− 0.47, − 0.32) | 543 | −0.14 (− 0.31, 0.03) | 97 | −0.26 (− 0.44, − 0.07) | 0.01 |
| 12 months | −0.42 (− 0.53, − 0.31) | 289 | −0.18 (− 0.41, 0.05) | 54 | −0.24 (− 0.49, − 0.01) | 0.06 |
| EQ-5D-5 L Usual activities (1–5, 1 is best) | ||||||
| Baseline | 2.87 (2.76. 2.98) | 696 | 2.74 (2.52, 2.96) | 121 | 0.28 | |
| 10 weeks | −0.57 (− 0.73, − 0.42) | 576 | −0.26 (− 0.62, 0.09) | 103 | −0.31 (− 0.70, 0.08) | 0.12 |
| 6 months | − 0.64 (− 0.72, − 0.54) | 540 | −0.34 (− 0.54, − 0.14) | 97 | −0.30 (− 0.52, − 0.08) | 0.01 |
| 12 months | −0.64 (− 0.77, − 0.52) | 290 | −0.38 (− 0.66, − 0.11) | 54 | −0.26 (− 0.56, 0.04) | 0.09 |
| EQ-5D-5 L Pain/discomfort (1–5, 1 is best) | ||||||
| Baseline | 2.65 (2.53. 2.76) | 693 | 2.66 (2.44, 2.89) | 121 | 0.87 | |
| 10 weeks | −0.21 (−0.28, − 0.13) | 577 | − 0.87 (− 0.36, 0.01) | 103 | −0.02 (− 0.21, 0.17) | 0.82 |
| 6 months | − 0.24 (− 0.33, − 0.15) | 537 | −0.13 (− 0.33. 0.06) | 97 | −0.11 (− 0.32, 0.11) | 0.33 |
| 12 months | − 0.23 (− 0.35, − 0.12) | 54 | −0.21 (− 0.47, 0.05) | 287 | − 0.03 (− 0.31, 0.26) | 0.85 |
| EQ-5D-5 L Anxiety/depression (1–5, 1 is best) | ||||||
| Baseline | 1.84 (1.75. 1.93) | 692 | 1.68 (1.49, 1.86) | 121 | 0.11 | |
| 10 weeks | −0.13 (−0.19, − 0.06) | 573 | −0.24 (− 0.39, − 0.10) | 102 | 0.12 (− 0.03, 0.27) | 0.12 |
| 6 months | −0.16 (− 0.23, − 0.10) | 528 | −0.10 (− 0.26, 0.05) | 95 | −0.06 (− 0.32, 0.11) | 0.48 |
| 12 months | − 0.19 (− 0.28, − 0.10) | 282 | −0.20 (− 0.39, 0.00) | 54 | 0.00 (− 0.21, 0.22) | 0.98 |
| EQ-5D-5 L Health today (0–100, 100 is high) | ||||||
| Baseline | 49.85 (48.02, 51.68) | 687 | 53.06 (49.16, 56.95) | 121 | 0.13 | |
| 10 weeks | 8.36 (6.89. 9.83) | 575 | 2.28 (−1.07, 5.62) | 103 | 6.08 (2.44, 9.72) | < 0.001 |
| 6 months | 9.14 (7.03, 11.25) | 528 | 1.52 (−2.86, 5.90) | 97 | 7.62 (2.87, 12.37) | < 0.001 |
| 12 months | 7.55 (5.33, 9.78) | 282 | 4.79 (−0.301, 9.88) | 54 | 2.76 (−2.80, 8.32) | 0.33 |
| SOC-13 Sense of coherence (13–91, 91 is high) | ||||||
| Baseline | 68.45 (67.34, 69.56) | 658 | 69.45 (67.13, 71,76) | 118 | 0.44 | |
| 10 weeks | 0.31 (−0.76, 1.38) | 539 | −1.41 (−3.56, 0.73) | 103 | 1.73 (−0.56, 4.01) | 0.14 |
| 6 months | 0.29 (−1.07, 1.66) | 496 | −2.62 (−5.29, 0.04) | 94 | 2.92 (0.08, 5.75) | 0.04 |
| 12 months | 0.71 (−1.04, 2.47) | 256 | 0.02 (−3.38, 3.43) | 51 | 0.69 (−3.02, 4.40) | 0.72 |
aAdjusted for the baseline mean value of each variable
bCOPM:Canadian Occupational Performance Measure
cSPPB: Short Physical Performance Measure Battery
dEQ-5D-5 L: European Quality of Life Scale
Fig. 2Changes in scores from the COPM-S and COPM-P tests in the control and reablement groups over time